Articles - Page 5 of 15 - Tumori Journal

From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching

Research ArticleBy giuliat December 14, 2025

Patients with HER2+ breast cancer (BC) can receive pertuzumab/trastuzumab (PT) subcutaneous (SC) or intravenous (IV) with similar efficacy. This study explores patients and healthcare professionals (HCPs) perceptions post-PT-SC implementation, alongside a pharmacoeconomic analysis.
This multicentre observational study included semi-structured interviews with HER2+ BC patients (SC or IV) and HCPs from six Lombardy (Italy) BC units plus a pharmacoeconomic analysis of organisational and cost impact. Data were analysed using descriptive statistics and thematic analysis to identify key themes: safety perception, treatment comfort, and trust issues.

Details

Letrozole for hormone receptor–positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial

Research ArticleBy giuliat December 14, 2025

Epidemiological and retrospective studies suggest that letrozole may improve outcomes in low-grade serous carcinoma of the ovary (LGSCO) by targeting estrogen-driven tumor progression.
We designed a multicenter, randomized, open-label, phase III trial to compare letrozole versus standard chemotherapy (carboplatin plus paclitaxel) in prolonging progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), quality of life (MENQoL), and musculoskeletal pain (BPI-SF).

Details

Volume 111 Issue 6, December 2025

Research ArticleBy giuliat December 4, 2025

Read the latest issue. It contains the following articles:
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives
Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations
The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations
An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project
Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL
Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry
Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC
Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis

Details

Abdominal specimen retrieval in endometrial cancer patients with large uteri

Research ArticleBy giuliat November 11, 2025

Endometrial cancer surgery has a low risk of specimen fragmentation, but removing large uteri can be challenging. This study aimed to assess whether the use of minilaparotomic incision for specimen retrieval compromises the benefits of minimally invasive surgery in endometrial cancer patients with a large uterus or utero-vaginal discrepancy.
This is a retrospective multi-institutional study, including endometrial cancer patients with FIGO 2009 clinical stage I–II, undergoing minimally invasive staging surgery (laparoscopic or robot-assisted) followed by minilaparotomic specimen retrieval. A propensity-matched algorithm was used to compare outcomes of minimally invasive staging with open surgery.

Details

Two years after the reform of Italian Ethics Committees: Time for reflection

EditorialBy giuliat November 11, 2025

The recent reform of Italian Ethics Committees (ECs), formalized between 2022 and 2023, aimed to streamline ethical oversight in clinical research by transitioning from a fragmented local system to a coordinated national framework. The new structure includes 40 Territorial Ethics Committees (CETs) and three National Committees (CENs), under the supervision of the National Coordination Centre (CCNCE). While the reform aligned Italy with European Regulation (EU) No 536/2014, significant implementation gaps remain.

Details

Trabectedin–irinotecan as a potential therapeutic option in desmoplastic small round cell tumor: A small case series

Case ReportBy giuliat November 9, 2025

Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive mesenchymal malignancy driven by the EWS–WT1 gene fusion. Prognosis remains poor despite intensive multimodal therapy. Preclinical studies indicate that trabectedin combined with irinotecan exerts synergistic antitumor effects in translocation-driven sarcomas.

Details

Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers

Case ReportBy giuliat November 9, 2025

Remarkable advancements in the therapeutic armamentarium for medullary thyroid cancer (MTC) have been observed in the last 10 years. The current understanding of driver mutations, such as RET and RAS, has enabled the development of new therapies for advanced and metastatic disease, demonstrating improved efficacy.

Details

Postoperative radiotherapy for stage IV breast cancer following primary tumor removal: Systematic review and meta-analysis

Review ArticleBy giuliat October 30, 2025

De novo metastatic breast cancer (dnMBC) is diagnosed when breast cancer has spread at presentation and accounts for 5–10% of cases. The benefit of postoperative radiotherapy (PORT) after primary tumor surgery in this setting remains uncertain.
We conducted a review and meta-analysis of observational studies published between 2013 and 2024. Two databases (PubMed and Embase) were searched and the review followed PRISMA 2020 guidelines.

Details

A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study

Research ArticleBy giuliat October 30, 2025

This study evaluates the activity of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma (mRCC) patients.
The NivoMet TWINS-GU002 Study was a prospective, multicentre, single-arm, phase II trial conducted in pre-treated mRCC patients eligible for nivolumab and without diabetes mellitus. Patients received nivolumab (240 mg every two weeks) plus metformin (500 mg orally twice a day) until disease progression.

Details

Pediatric palliative care in patients with brain tumors: Timing, activation, and management of acute events

Research ArticleBy giuliat October 22, 2025

The highest percentage of our patients referred to Pediatric Palliative Care (PPC) are those with brain tumors. Of these, we analyzed PPC activation modes and timing, occurrence of acute events during the period of PPC activation, and the time between acute event and death.
During the period 1 January 2010 to 31 October 2023 approximately 1000 Cranial Nervous System (CNS) tumor patients were treated at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan.

Details